Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19/CD22 CAR-T for R/R B-cell Lymphoma
NCT05651100Phase 2Not yet recruiting
- Sponsor
- Beijing Kecellitics Biotech Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-CD19 CAR-T cells in B-cell non-Hodgkin lymphoma, sponsored by Beijing Kecellitics Biotech Co., Ltd.. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05651100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651100.